Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase II Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Algernon Pharmaceuticals, Inc. announced positive topline data showing that it has met the co-primary endpoint in its Phase II proof of concept study evaluating NP-120 for the potential treatment of idiopathic pulmonary fibrosis and chronic cough.